Literature DB >> 19960263

Acute improvement of cardiac efficiency measured by 11C-acetate PET after cardiac resynchronization therapy and clinical outcome.

Kenji Kitaizumi1, Kazushi Yukiiri, Hisashi Masugata, Hiroyuki Takinami, Yasuyoshi Iwado, Takahisa Noma, Naohisa Hosomi, Koji Ohmori, Shoichi Senda, Masakazu Kohno.   

Abstract

The purpose of this study was to examine the usefulness of (11)C-acetate positron emission tomography (PET) for assessing the efficacy of cardiac resynchronization therapy (CRT). Enrolled in this study were 20 patients with severe heart failure. All patients underwent 11C-acetate PET within 1 week after CRT. The oxygen consumption was measured by the monoexponential clearance rate of 11C-acetate (K(mono)) for both CRT-off and -on. Cardiac efficiency (CE) was determined using the concept of the work metabolic index (WMI). WMI was calculated as WMI = (stroke volume index) x (systolic blood pressure) x (heart rate)/K(mono). The patients were divided into two groups: 14 patients with improved CE (from 5.27 +/- 0.91 to 6.77 +/- 1.12) and 6 patients with deteriorated CE (from 5.35 +/- 0.92 to 4.86 +/- 0.84) by CRT-on. K(mono) decreased from 0.053 +/- 0.006 to 0.046 +/- 0.003 by CRT-on in the improved CE group (p = 0.028), but increased from 0.049 +/- 0.006 to 0.050 +/- 0.006 in the deteriorated-CE group (p = 0.036). Stroke volume index, systolic blood pressure, and heart rate did not change by CRT-on for either group. At the one-year follow-up, there were significantly higher rates of major cardiac adverse events in the deteriorated-CE group than in the improved-CE group (p = 0.032). Therefore, the improvement of CE, as assessed by 11C-acetate PET in the early period after CRT, is produced by the decrease in oxygen consumption in patients showing good responses to CRT. The decrease in oxygen consumption in the early period after CRT is thus a useful marker for predicting a good clinical outcome after CRT.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19960263     DOI: 10.1007/s10554-009-9549-8

Source DB:  PubMed          Journal:  Int J Cardiovasc Imaging        ISSN: 1569-5794            Impact factor:   2.357


  20 in total

1.  Left ventricular dyssynchrony predicts benefit of cardiac resynchronization therapy in patients with end-stage heart failure before pacemaker implantation.

Authors:  Jeroen J Bax; Thomas H Marwick; Sander G Molhoek; Gabe B Bleeker; Lieselot van Erven; Eric Boersma; Paul Steendijk; Ernst E van der Wall; Martin J Schalij
Journal:  Am J Cardiol       Date:  2003-11-15       Impact factor: 2.778

2.  Cardiac resynchronization in chronic heart failure.

Authors:  William T Abraham; Westby G Fisher; Andrew L Smith; David B Delurgio; Angel R Leon; Evan Loh; Dusan Z Kocovic; Milton Packer; Alfredo L Clavell; David L Hayes; Myrvin Ellestad; Robin J Trupp; Jackie Underwood; Faith Pickering; Cindy Truex; Peggy McAtee; John Messenger
Journal:  N Engl J Med       Date:  2002-06-13       Impact factor: 91.245

3.  Effect of cardiac resynchronization therapy on global and regional oxygen consumption and myocardial blood flow in patients with non-ischaemic and ischaemic cardiomyopathy.

Authors:  Oliver Lindner; Jürgen Vogt; Annett Kammeier; Peter Wielepp; Jens Holzinger; Detlev Baller; Barbara Lamp; Bert Hansky; Reiner Körfer; Dieter Horstkotte; Wolfgang Burchert
Journal:  Eur Heart J       Date:  2004-11-30       Impact factor: 29.983

Review 4.  Critical appraisal of methods to assess mechanical dyssynchrony.

Authors:  Cheuk-Man Yu; Jeroen J Bax; John Gorcsan
Journal:  Curr Opin Cardiol       Date:  2009-01       Impact factor: 2.161

5.  Long-term prognosis after cardiac resynchronization therapy is related to the extent of left ventricular reverse remodeling at midterm follow-up.

Authors:  Claudia Ypenburg; Rutger J van Bommel; C Jan Willem Borleffs; Gabe B Bleeker; Eric Boersma; Martin J Schalij; Jeroen J Bax
Journal:  J Am Coll Cardiol       Date:  2009-02-10       Impact factor: 24.094

6.  Myocardial efficiency during levosimendan infusion in congestive heart failure.

Authors:  H Ukkonen; M Saraste; J Akkila; J Knuuti; M Karanko; H Iida; P Lehikoinen; K Någren; L Lehtonen; L M Voipio-Pulkki
Journal:  Clin Pharmacol Ther       Date:  2000-11       Impact factor: 6.875

7.  The effect of cardiac resynchronization on morbidity and mortality in heart failure.

Authors:  John G F Cleland; Jean-Claude Daubert; Erland Erdmann; Nick Freemantle; Daniel Gras; Lukas Kappenberger; Luigi Tavazzi
Journal:  N Engl J Med       Date:  2005-03-07       Impact factor: 91.245

8.  Acute effects of dobutamine on myocardial oxygen consumption and cardiac efficiency measured using carbon-11 acetate kinetics in patients with dilated cardiomyopathy.

Authors:  R S Beanlands; D S Bach; R Raylman; W F Armstrong; V Wilson; M Montieth; C K Moore; E Bates; M Schwaiger
Journal:  J Am Coll Cardiol       Date:  1993-11-01       Impact factor: 24.094

9.  Usefulness of baseline electrocardiographic QRS complex pattern to predict response to cardiac resynchronization.

Authors:  Evan C Adelstein; Samir Saba
Journal:  Am J Cardiol       Date:  2008-11-12       Impact factor: 2.778

10.  Measures of left ventricular dyssynchrony and the correlation to clinical and echocardiographic response after cardiac resynchronization therapy.

Authors:  Raed Abdelhadi; Evan Adelstein; Andrew Voigt; John Gorcsan; Samir Saba
Journal:  Am J Cardiol       Date:  2008-06-18       Impact factor: 2.778

View more
  6 in total

Review 1.  SPECT and PET in ischemic heart failure.

Authors:  George Angelidis; Gregory Giamouzis; Georgios Karagiannis; Javed Butler; Ioannis Tsougos; Varvara Valotassiou; George Giannakoulas; Nikolaos Dimakopoulos; Andrew Xanthopoulos; John Skoularigis; Filippos Triposkiadis; Panagiotis Georgoulias
Journal:  Heart Fail Rev       Date:  2017-03       Impact factor: 4.214

2.  The effect of device-based cardiac contractility modulation therapy on myocardial efficiency and oxidative metabolism in patients with heart failure.

Authors:  Georg Goliasch; Aliasghar Khorsand; Matthias Schütz; Georgios Karanikas; Cesar Khazen; Heinz Sochor; Herwig Schmidinger; Michael Wolzt; Senta Graf
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-11-15       Impact factor: 9.236

Review 3.  Sex differences in device therapy for heart failure: utilization, outcomes, and adverse events.

Authors:  Naomi D Herz; Joseph Engeda; Robbert Zusterzeel; William E Sanders; Kathryn M O'Callaghan; David G Strauss; Samantha B Jacobs; Kimberly A Selzman; Ileana L Piña; Daniel A Caños
Journal:  J Womens Health (Larchmt)       Date:  2015-03-20       Impact factor: 2.681

4.  Evidence of scar tissue: contra-indication to cardiac resynchronization therapy?

Authors:  E E van der Wall; M J Schalij; H F Verwey; J J Bax
Journal:  Int J Cardiovasc Imaging       Date:  2010-07-08       Impact factor: 2.357

Review 5.  Cardiovascular imaging 2010 in the International Journal of Cardiovascular Imaging.

Authors:  Ricardo A Costa; Johan H C Reiber; Frank J Rybicki; Paul Schoenhagen; Arthur A Stillman; Johan de Sutter; Nico R L van de Veire; Ernst E van der Wall
Journal:  Int J Cardiovasc Imaging       Date:  2011-02-24       Impact factor: 2.357

6.  Myocardial tissue and metabolism characterization in men with alcohol consumption by cardiovascular magnetic resonance and 11C-acetate PET/CT.

Authors:  Shuai Liu; Xue Lin; Ximin Shi; Ligang Fang; Li Huo; Fei Shang; Juhani Knuuti; Chunlei Han; Xiaomeng Wu; Rui Guo; Haiyan Ding; Runhua Zhang; Huimin Duan; Jie Ding; Haiqun Xing; Xihai Zhao
Journal:  J Cardiovasc Magn Reson       Date:  2020-04-16       Impact factor: 5.364

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.